Cumulative Absolute Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors: A PanCareSurFup Study
Journal of Clinical Oncology · 20.01.2024 · 42 (3) · 336-347
DOI: 10.1200/jco.23.00452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2024. Verfasst von Emma J Heymer und 28 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom. Hauptthemen laut MEDLINE: Cancer Survivors, Neoplasms, Second Primary, Colorectal Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Childhood cancer survivors are at the risk of developing subsequent colorectal cancers (CRCs), but the absolute risks by treatment modality are uncertain. We quantified the absolute risks by radiotherapy treatment characteristics using clinically accessible data from a Pan-European wide case-control study nested within a large cohort of childhood cancer survivors: the PanCareSurFup Study. METHODS Odds ratios (ORs) from a case-control study comprising 143 CRC cases and 143 controls nested within a cohort of 69,460 survivors were calculated. These, together with standardized incidence ratios for CRC for this cohort and European general population CRC incidence rates and survivors' mortality rates, were used to estimate cumulative absolute risks (CARs) by attained age for different categories of radiation to the abdominopelvic area. RESULTS Overall, survivors treated with abdominopelvic radiotherapy treatment (ART) were three times more likely to develop a subsequent CRC than those who did not receive ART (OR, 3.1 [95% CI, 1.4 to 6.6]). For male survivors treated with ART, the CAR was 0.27% (95% CI, 0.17 to 0.59) by age 40 years, 1.08% (95% CI, 0.69 to 2.34) by age 50 years (0.27% expected in the general population), and 3.7% (95% CI, 2.36 to 7.80) by age 60 years (0.95% expected). For female survivors treated with ART, the CAR was 0.29% (95% CI, 0.18 to 0.62) by age 40 years, 1.03% (95% CI, 0.65 to 2.22) by age 50 years (0.27% expected), and 3.0% (95% CI, 1.91 to 6.37) by age 60 years (0.82% expected). CONCLUSION We demonstrated that by age 40 years survivors of childhood cancer treated with ART already have a similar risk of CRC as those age 50 years in the general population for whom population-based CRC screening begins in many countries. This information should be used in the development of survivorship guidelines for the risk stratification of survivors concerning CRC risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.
- Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- Emma Children's Hospital, Amsterdam UMC, Amsterdam, the Netherlands.
- Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, INSERM U1018, Gustave Roussy, University Paris Saclay, Villejuif, France.
- Department of Clinical Sciences Lund, Paediatrics,Skane University Hospital, Lund University, Lund, Sweden.
ORCID-Profile: Emma J Heymer, Katarzyna Jóźwiak, David L Winter, Florent de Vathaire, Judith L Kok, Helena J H van der Pal, Lars Hjorth, Zsuzsanna Jakab, Milena M Maule, Riccardo Haupt, Francesca Bagnasco, Ibrahima Diallo, Grit Sommer, Lorna Zadravec Zaletel, Claudia E Kuehni, Jeanette F Winther, Päivi M Lähteenmäki, Rodrigue S Allodji, Roderick Skinner, Cécile M Ronckers, Michael M Hawkins, Raoul C Reulen, Jop C Teepen
Zitieren
APA
Heymer, E. J., Jóźwiak, K., Kremer, L. C., Winter, D. L., de Vathaire, F., Sunguc, C., Sugden, E., Kok, J. L., van der Pal, H. J. H., Hjorth, L., Jakab, Z., Maule, M. M., Haupt, R., Bagnasco, F., Terenziani, M., Diallo, I., Gunnes, M. W., Sommer, G., Zadravec Zaletel, L., …, & Teepen, J. C. (2024). Cumulative Absolute Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors: A PanCareSurFup Study. Journal of Clinical Oncology, 42(3), 336-347. https://doi.org/10.1200/jco.23.00452
Vancouver
Heymer EJ, Jóźwiak K, Kremer LC, Winter DL, de Vathaire F, Sunguc C, et al. Cumulative Absolute Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors: A PanCareSurFup Study. Journal of Clinical Oncology. 2024;42(3):336-347. doi:10.1200/jco.23.00452
BibTeX
@article{Heymer2024,
author = {Heymer, Emma J and Jóźwiak, Katarzyna and Kremer, Leontien C and Winter, David L and de Vathaire, Florent and Sunguc, Ceren and Sugden, Elaine and Kok, Judith L and van der Pal, Helena J H and Hjorth, Lars and Jakab, Zsuzsanna and Maule, Milena M and Haupt, Riccardo and Bagnasco, Francesca and Terenziani, Monica and Diallo, Ibrahima and Gunnes, Maria W and Sommer, Grit and Zadravec Zaletel, Lorna and Kuehni, Claudia E and Winther, Jeanette F and Lähteenmäki, Päivi M and Gudmundsdottir, Thorgerdur and Allodji, Rodrigue S and Skinner, Roderick and Ronckers, Cécile M and Hawkins, Michael M and Reulen, Raoul C and Teepen, Jop C},
title = {Cumulative Absolute Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors: A PanCareSurFup Study},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {3},
pages = {336--347},
doi = {10.1200/jco.23.00452}
}
EUVIMED